MorphoSys Revenue and Competitors

Planegg, Germany

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MorphoSys's estimated annual revenue is currently $162.7M per year.(i)
  • MorphoSys's estimated revenue per employee is $133,478
  • MorphoSys's current valuation is $1.2B. (January 2022)

Employee Data

  • MorphoSys has 1219 Employees.(i)
  • MorphoSys grew their employee count by 33% last year.

MorphoSys's People

NameTitleEmail/Phone
1
Chief Staff to CEO and VP, Head Corporate Strategy & Commercial Alliance ManagementReveal Email/Phone
2
Executive Assistant to Chief Commercial OfficerReveal Email/Phone
3
Head MSAT Process Science @ RocheReveal Email/Phone
4
Head Communications and Patient AdvocacyReveal Email/Phone
5
Head Global QA OperationsReveal Email/Phone
6
VP - Global Head Investor Relations & SustainabilityReveal Email/Phone
7
Head Translational Research / VPReveal Email/Phone
8
VP, US Head Human ResourcesReveal Email/Phone
9
Head ESOReveal Email/Phone
10
Executive Assistant to the Chief Legal OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$176250M236276-1%$1M$2.3T
#2
$1.7M10N/AN/AN/A
Add Company

What Is MorphoSys?

MorphoSys is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates. MorphoSys is listed on the Frankfurt Stock Exchange and NASDAQ under the symbol MOR. Headquartered in Planegg near Munich, Germany and the MorphoSys group includs the fully owned U.S. subsidiary MorphoSys US Inc. based in Boston, MA.

keywords:N/A

N/A

Total Funding

1219

Number of Employees

$162.7M

Revenue (est)

33%

Employee Growth %

$1.2B

Valuation

N/A

Accelerator

MorphoSys News

2022-04-13 - MorphoSys (NASDAQ:MOR) Rating Increased to Buy at Zacks ...

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The...

2022-04-06 - Brokerages Set MorphoSys AG (ETR:MOR) Price Target at ...

Deutsche Bank Aktiengesellschaft set a €30.00 ($32.61) target price on MorphoSys in a research report on Tuesday, March 22nd. Berenberg Bank set...

2022-04-06 - Should You Buy Morphosys Ag (MOR) Stock Wednesday?

Morphosys Ag (MOR) stock is down -70.35% over the last 12 months, and the average rating from Wall Street analysts is a Hold.

2021-11-10 - MorphoSys Announces Departure of Roland Wandeler

Media Release MorphoSys Announces Departure of Roland Wandeler Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys M ...

2021-11-10 - MorphoSys Announces Departure of Roland Wandeler

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Announces Departure of Roland Wandeler 09.11.2021 / 22:01 The issuer is solely responsible for the content of this announcement. Media Release MorphoSys Announces Departure of Roland Wandeler Planegg/Munich, Germany, November 9 ...